<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01904136</url>
  </required_header>
  <id_info>
    <org_study_id>2012-0708</org_study_id>
    <secondary_id>NCI-2013-02183</secondary_id>
    <secondary_id>RP110553 05-07-04832</secondary_id>
    <secondary_id>05-07-04832</secondary_id>
    <secondary_id>P01 - 5P01</secondary_id>
    <secondary_id>2012-0708</secondary_id>
    <secondary_id>P01CA049639</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT01904136</nct_id>
  </id_info>
  <brief_title>Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia</brief_title>
  <official_title>A Phase I/II Clinical Trial of NK Cells Administration to Prevent Disease Relapse for Patient With High-Risk Myeloid Malignancies Undergoing Haploidentical Stem-Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II studies the side effects and best dose of natural killer cells before and
      after donor stem cell transplant and to see how well they work in treating patients with
      acute myeloid leukemia, myelodysplastic syndrome, or chronic myelogenous leukemia. Giving
      chemotherapy with or without total body irradiation before a donor peripheral blood stem cell
      or bone marrow transplant helps stop the growth of cancer cells. It may also stop the
      patient's immune system from rejecting the donor's stem cells. When the healthy stem cells
      and natural killer cells from a donor are infused into the patient they may help the
      patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate safety, tolerability and identify the maximum tolerated dose (MTD) of expanded
      natural killer (NK) cells to be used in patients with myeloid malignancies undergoing a
      haploidentical stem-cell transplant (HaploSCT).

      SECONDARY OBJECTIVES:

      I. To determine survival of NK cells in vivo post-transplant. II. To determine the function
      of NK cells post-transplant and compare with a retrospective control treated with no NK
      cells.

      III. To estimate the proportion of patients with engraftment/graft failure. IV. To estimate
      the non-relapse mortality (NRM) at day 100 post-transplant. V. To estimate the cumulative
      incidence of grade III-IV aGVHD (acute graft-versus-host disease) at day 100.

      VI. To assess the rate of chronic graft-versus-host disease (GVHD) within the first year post
      transplantation.

      VII. To assess immune reconstitution post-transplant. VIII. To assess disease response,
      disease-free survival (DFS) and overall survival (OS) after transplantation.

      IX. To perform a retrospective comparison of patients treated on the study with NK cells will
      be performed with a Center for International Blood and Marrow Transplant Research (CIBMTR)
      control of similar patients who did not receive NK cells.

      OUTLINE: This is a phase I, dose-escalation study of NK cells followed by a phase II study.
      Patients are assigned to 1 of 2 conditioning regimens.

      MYELOABLATIVE CONDITIONING REGIMEN: Patients receive high-dose melphalan intravenously (IV)
      over 30 minutes on day -7, fludarabine phosphate IV over 1 hour on days -7 to -4, undergo
      total-body irradiation (TBI) on day -3, and NK cells IV over 30 minutes on day -2 or -1.

      NON-MYELOABLATIVE CONDITIONING REGIMEN: Patients receive melphalan IV over 30 minutes on day
      -7, fludarabine phosphate IV over 1 hour on days -7 to -4, undergo TBI on day -3, and receive
      NK cells IV over 30 minutes on day -2 or -1.

      TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell (PBSC) or bone marrow
      transplant on day 0.

      POST-TRANSPLANT CYCLOPHOSPHAMIDE AND GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV
      over 3 hours on days 3 and 4, tacrolimus IV beginning on day 5 for 2 weeks and then orally
      (PO) for approximately 4 months, and mycophenolate mofetil PO thrice daily (TID) beginning on
      day 5 for approximately 6-7 months.

      NK CELLS: Patients receive NK cells IV over 30 minutes on days 7 and 28-90.

      After completion of study treatment, patients are followed up for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 22, 2014</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated doses (MTD) of natural killer (NK) cells</measure>
    <time_frame>Up to day 70 post-transplant</time_frame>
    <description>Will be defined by incidence of dose limiting toxicity including death, grade 3-4 toxicities, graft failure, or grade 3-4 graft versus host disease (GVHD). Dose-finding will be carried out using the time-to-event continual reassessment method of Cheung and Chappell. All adverse events will be tabulated by dose, and the fitted dose-toxicity curve will be summarized.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>100-day treatment related mortality</measure>
    <time_frame>Up to 100 days post-transplant</time_frame>
    <description>Will be defined as death due to any cause without disease recurrence within 100 days post stem cell transplant (SCT). The method of Thall and Sung will be used, based on an historical rate of 35%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be estimated using the Kaplan-Meier method, and distributions will be compared using log-rank tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be estimated using the Kaplan-Meier method, and distributions will be compared using log-rank tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to engraftment</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be estimated using the Kaplan-Meier method, and distributions will be compared using log-rank tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to graft failure</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be estimated using the Kaplan-Meier method, and distributions will be compared using log-rank tests.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome</condition>
  <condition>Acute Myeloid Leukemia in Remission</condition>
  <condition>Acute Myeloid Leukemia With Gene Mutations</condition>
  <condition>Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission</condition>
  <condition>de Novo Myelodysplastic Syndrome</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Previously Treated Myelodysplastic Syndrome</condition>
  <condition>Recurrent Acute Myeloid Leukemia</condition>
  <condition>Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Therapy-Related Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (NK cells, allogeneic stem cell transplant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MYELOABLATIVE CONDITIONING REGIMEN: Patients receive high-dose melphalan IV over 30 minutes on day -7, fludarabine phosphate IV over 1 hour on days -7 to -4, undergo TBI on day -3, and NK cells IV over 30 minutes on day -2 or -1.
NON-MYELOABLATIVE CONDITIONING REGIMEN: Patients receive melphalan IV over 30 minutes on day -7, fludarabine phosphate IV over 1 hour on days -7 to -4, undergo TBI on day -3, and receive NK cells IV over 30 minutes on day -2 or -1.
TRANSPLANT: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.
POST-TRANSPLANT CYCLOPHOSPHAMIDE AND GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4, tacrolimus IV beginning on day 5 for 2 weeks and then PO for approximately 4 months, and mycophenolate mofetil PO TID beginning on day 5 for approximately 6-7 months.
NK CELLS: Patients receive NK cells IV over 30 minutes on days 7 and 28-90.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic PBSC or bone marrow transplant</description>
    <arm_group_label>Treatment (NK cells, allogeneic stem cell transplant)</arm_group_label>
    <other_name>Allogeneic Hematopoietic Cell Transplantation</other_name>
    <other_name>Allogeneic Stem Cell Transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone Marrow Transplantation</intervention_name>
    <description>Undergo allogeneic PBSC or bone marrow transplant</description>
    <arm_group_label>Treatment (NK cells, allogeneic stem cell transplant)</arm_group_label>
    <other_name>BMT</other_name>
    <other_name>Bone Marrow Grafting</other_name>
    <other_name>Bone marrow transplant</other_name>
    <other_name>Marrow Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (NK cells, allogeneic stem cell transplant)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (NK cells, allogeneic stem cell transplant)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (NK cells, allogeneic stem cell transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (NK cells, allogeneic stem cell transplant)</arm_group_label>
    <other_name>Alanine Nitrogen Mustard</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine Mustard</other_name>
    <other_name>L-sarcolysin</other_name>
    <other_name>L-Sarcolysin Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysine</other_name>
    <other_name>Melphalanum</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine nitrogen mustard</other_name>
    <other_name>Sarcoclorin</other_name>
    <other_name>Sarkolysin</other_name>
    <other_name>WR-19813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (NK cells, allogeneic stem cell transplant)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Natural Killer Cell Therapy</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (NK cells, allogeneic stem cell transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic PBSC or bone marrow transplant</description>
    <arm_group_label>Treatment (NK cells, allogeneic stem cell transplant)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSCT</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>Peripheral Stem Cell Support</other_name>
    <other_name>Peripheral Stem Cell Transplant</other_name>
    <other_name>Peripheral Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV and PO</description>
    <arm_group_label>Treatment (NK cells, allogeneic stem cell transplant)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (NK cells, allogeneic stem cell transplant)</arm_group_label>
    <other_name>Total Body Irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligibility for pediatric patients will be determined in conjunction with an MD
             Anderson Cancer Center (MDACC) pediatrician; patients age 2-17 years old may be
             enrolled after at least 4 adults (ages 18-65 years old) have been treated without
             toxicity

          -  Patient with no matched related donor who has a related haploidentical donor
             identified (=&lt; 7/8 allele match at the A, B, C, DR loci) who is willing to undergo a
             bone marrow harvest and an NK cell collection approximately 2 weeks of the recipient's
             admission for transplant; the donor must be 16 years of age or older and weigh at
             least 110 pounds

          -  Patients with one of the following diseases: acute myeloid leukemia (AML): a. first
             complete remission with high-risk features defined as: (i) greater than 1 cycle of
             induction therapy required to achieve remission; (ii) preceding myelodysplastic
             syndrome (MDS); (iii) presence of FLT3 mutations or internal tandem duplication or
             other mutations associated with poor-risk AML (e.g. DNMT3A, TET2); (iv)
             French-American-British Classification (FAB) M6 or M7 classification; (v) adverse
             cytogenetics: -5, deletion (del) 5q, -7, del7q, abnormalities involving 3q, 9q, 11q,
             20q, 21q, 17, +8 or complex karyotype (&gt; 3 abnormalities); (vi) treatment-related AML,
             or b. second or greater remission; patients beyond second remission have to be in
             complete remission (CR) at transplant to be eligible, or c. primary induction failure
             with partial response to therapy who achieve adequate cytoreduction

          -  Patients with myelodysplastic syndromes (MDS): a. de novo MDS with intermediate or
             high-risk International Prognostic Scoring System (IPSS) scores; patients with
             intermediate-1 features should have failed to respond to hypomethylating agent
             therapy, or b. patients with treatment-related MDS

          -  Chronic myeloid leukemia (CML): a. failed to achieve cytogenetic remission or have
             cytogenetic relapse after treatment with at least 2 tyrosine kinase inhibitors, or b.
             accelerated phase or blast phase at any time

          -  Performance score of at least 70% by Karnofsky or 0 to 1 by Eastern Cooperative
             Oncology Group (ECOG) (age &gt;= 12 years), or Lansky Play-performance scale of at least
             70% or greater (age &lt; 12 years)

          -  Serum creatinine clearance equal or more than 50 ml/min (calculated with
             Cockcroft-Gault formula)

          -  Bilirubin equal or less than 1.5 mg/dl except for Gilbert's disease

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) equal or less than
             200 IU/ml for adults

          -  Conjugated (direct) bilirubin less than 2 x upper limit of normal

          -  Left ventricular ejection fraction equal or greater than 40%

          -  Diffusing capacity of the lung for carbon monoxide (DLCO) equal or greater than 50%
             predicted corrected for hemoglobin; for children =&lt; 7 years of age who are unable to
             perform pulmonary function tests (PFT), oxygen saturation &gt;= 92% on room air by pulse
             oximetry

          -  Patient or patient's legal representative, parent(s) or guardian should provide
             written informed consent; assent of a minor if participant's age is at least seven and
             less than eighteen years

        Exclusion Criteria:

          -  Human immunodeficiency virus (HIV) positive; active hepatitis B or C

          -  Uncontrolled infections; principal investigator (PI) is the final arbiter of this
             criterion

          -  Liver cirrhosis

          -  Central nervous system (CNS) involvement within 3 months

          -  Positive pregnancy test in a woman with child bearing potential defined as not
             post-menopausal for 12 months or no previous surgical sterilization

          -  Inability to comply with medical therapy or follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan O Ciurea</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 17, 2013</study_first_submitted>
  <study_first_submitted_qc>July 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2013</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Accelerated Phase</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

